AU2013234099B2 - Porous carbon particles for use in the treatment or prevention of liver disease - Google Patents
Porous carbon particles for use in the treatment or prevention of liver disease Download PDFInfo
- Publication number
- AU2013234099B2 AU2013234099B2 AU2013234099A AU2013234099A AU2013234099B2 AU 2013234099 B2 AU2013234099 B2 AU 2013234099B2 AU 2013234099 A AU2013234099 A AU 2013234099A AU 2013234099 A AU2013234099 A AU 2013234099A AU 2013234099 B2 AU2013234099 B2 AU 2013234099B2
- Authority
- AU
- Australia
- Prior art keywords
- carbon
- disease
- liver
- porous carbon
- carbon particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1204696.7A GB201204696D0 (en) | 2012-03-16 | 2012-03-16 | Therapy |
| GB1204696.7 | 2012-03-16 | ||
| PCT/GB2013/050673 WO2013136094A1 (en) | 2012-03-16 | 2013-03-15 | Porous carbon particles for use in the treatment or prevention of liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013234099A1 AU2013234099A1 (en) | 2014-10-02 |
| AU2013234099B2 true AU2013234099B2 (en) | 2017-03-30 |
Family
ID=46052080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013234099A Active AU2013234099B2 (en) | 2012-03-16 | 2013-03-15 | Porous carbon particles for use in the treatment or prevention of liver disease |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9844568B2 (enExample) |
| EP (2) | EP2825181B1 (enExample) |
| JP (2) | JP6293680B2 (enExample) |
| KR (2) | KR102441934B1 (enExample) |
| CN (1) | CN104363916B (enExample) |
| AU (1) | AU2013234099B2 (enExample) |
| BR (1) | BR112014022810B1 (enExample) |
| DK (1) | DK2825181T3 (enExample) |
| EA (1) | EA038965B1 (enExample) |
| GB (1) | GB201204696D0 (enExample) |
| IN (1) | IN2014DN07637A (enExample) |
| MY (1) | MY169093A (enExample) |
| NZ (1) | NZ631429A (enExample) |
| SG (1) | SG11201405771QA (enExample) |
| WO (1) | WO2013136094A1 (enExample) |
| ZA (1) | ZA201406989B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
| ES2727153T3 (es) * | 2014-04-17 | 2019-10-14 | Immutrix Therapeutics Inc | Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas |
| TWI607765B (zh) * | 2014-08-27 | 2017-12-11 | Kureha Corp | Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents |
| KR102328323B1 (ko) | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| EP3476818A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved carbon source |
| EP3476817A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved amphiphilic species |
| WO2019131209A1 (ja) * | 2017-12-27 | 2019-07-04 | 株式会社クラレ | 活性炭およびその製法 |
| JP7228498B2 (ja) * | 2018-10-24 | 2023-02-24 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
| WO2020085282A1 (ja) * | 2018-10-24 | 2020-04-30 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
| JP7338993B2 (ja) * | 2019-03-06 | 2023-09-05 | 株式会社クラレ | 多孔質炭素および多孔質炭素の製造方法 |
| JP7061640B2 (ja) * | 2019-04-16 | 2022-04-28 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
| WO2020213559A1 (ja) * | 2019-04-16 | 2020-10-22 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
| JP7563145B2 (ja) * | 2019-12-05 | 2024-10-08 | ａｒｔｉｅｎｃｅ株式会社 | 多孔質炭素及びその製造方法 |
| WO2024261472A1 (en) * | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Porous carbon particles for use in therapy |
| KR102971111B1 (ko) | 2023-09-05 | 2026-06-02 | 한국생산기술연구원 | 열경화성 에폭시 조성물, 이의 경화물 및 용도 |
| CN121925310A (zh) * | 2025-03-28 | 2026-04-24 | 大阪燃气化学有限公司 | 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法 |
| JP7724390B1 (ja) * | 2025-03-28 | 2025-08-15 | 大阪ガスケミカル株式会社 | 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1525886A1 (en) * | 2003-10-22 | 2005-04-27 | Kureha Chemical Industry Co., Ltd. | Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5332637B2 (enExample) * | 1973-05-09 | 1978-09-09 | ||
| JPS51151693A (en) | 1975-06-23 | 1976-12-27 | Eisai Co Ltd | Coated bead-like activated carbon for blood purification |
| JPS5673542A (en) | 1979-11-22 | 1981-06-18 | Kureha Chem Ind Co Ltd | Adsorbent |
| JPS5731864A (en) * | 1980-08-04 | 1982-02-20 | Teijin Ltd | Oral activated carbon microcapsule |
| RU2177319C2 (ru) * | 1999-03-30 | 2001-12-27 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения гиперэндотоксинемии |
| GB0019417D0 (en) | 2000-08-09 | 2000-09-27 | Mat & Separations Tech Int Ltd | Mesoporous carbons |
| JP3522708B2 (ja) | 2001-04-11 | 2004-04-26 | 呉羽化学工業株式会社 | 経口投与用吸着剤 |
| JP4311923B2 (ja) * | 2002-10-07 | 2009-08-12 | 株式会社クレハ | 経口投与用肝疾患治療又は予防剤 |
| EP1407772B9 (en) | 2002-10-09 | 2007-02-21 | Kureha Corporation | Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases |
| CA2504517C (en) | 2002-11-01 | 2008-08-12 | Kureha Corporation | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| JP2005089306A (ja) * | 2003-09-12 | 2005-04-07 | Ajinomoto Co Inc | 炎症性腸疾患治療用の経直腸投与製剤 |
| JP4382629B2 (ja) * | 2003-10-22 | 2009-12-16 | 株式会社クレハ | 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤 |
| TWI370013B (en) * | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| TWI370012B (en) | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| JP2007045775A (ja) | 2005-08-11 | 2007-02-22 | Japan Organo Co Ltd | 含水活性炭及びその製造方法 |
| DE102005062160A1 (de) | 2005-12-19 | 2007-06-21 | BLüCHER GMBH | Aktivkohle für die medizinische Verwendung |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| CA2660883C (en) | 2006-10-09 | 2014-12-09 | British American Tobacco (Investments) Limited | Carbonising and/or activating carbonaceous material |
| BRPI0719161A2 (pt) | 2006-10-09 | 2014-02-04 | British American Tobacco Co | Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo. |
| WO2010138519A2 (en) | 2009-05-27 | 2010-12-02 | Ocera Therapeutics, Inc. | Use of adsorbent carbon microspheres for the treatment of pruritus |
| GB0921528D0 (en) * | 2009-12-09 | 2010-01-27 | Mast Carbon Internat Ltd | Carbon and its use in blood cleansing applications |
| PL2538930T3 (pl) | 2010-02-23 | 2016-11-30 | Preparaty do doustnego dostarczania środków adsorbujących do jelita | |
| JP5984352B2 (ja) * | 2010-10-12 | 2016-09-06 | フタムラ化学株式会社 | 経口投与用医薬用吸着剤の製造方法 |
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
-
2012
- 2012-03-16 GB GBGB1204696.7A patent/GB201204696D0/en not_active Ceased
-
2013
- 2013-03-15 JP JP2014561519A patent/JP6293680B2/ja active Active
- 2013-03-15 DK DK13711116.7T patent/DK2825181T3/da active
- 2013-03-15 WO PCT/GB2013/050673 patent/WO2013136094A1/en not_active Ceased
- 2013-03-15 EP EP13711116.7A patent/EP2825181B1/en active Active
- 2013-03-15 BR BR112014022810-8A patent/BR112014022810B1/pt active IP Right Grant
- 2013-03-15 US US14/385,332 patent/US9844568B2/en active Active
- 2013-03-15 KR KR1020207022420A patent/KR102441934B1/ko active Active
- 2013-03-15 CN CN201380025257.6A patent/CN104363916B/zh active Active
- 2013-03-15 SG SG11201405771QA patent/SG11201405771QA/en unknown
- 2013-03-15 NZ NZ631429A patent/NZ631429A/en unknown
- 2013-03-15 IN IN7637DEN2014 patent/IN2014DN07637A/en unknown
- 2013-03-15 AU AU2013234099A patent/AU2013234099B2/en active Active
- 2013-03-15 MY MYPI2014002656A patent/MY169093A/en unknown
- 2013-03-15 EA EA201491690A patent/EA038965B1/ru unknown
- 2013-03-15 KR KR1020147029083A patent/KR102142504B1/ko active Active
- 2013-03-15 EP EP19211615.0A patent/EP3650031B1/en active Active
-
2014
- 2014-09-25 ZA ZA2014/06989A patent/ZA201406989B/en unknown
-
2018
- 2018-02-14 JP JP2018023609A patent/JP6647570B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1525886A1 (en) * | 2003-10-22 | 2005-04-27 | Kureha Chemical Industry Co., Ltd. | Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102441934B1 (ko) | 2022-09-08 |
| DK2825181T3 (da) | 2020-04-14 |
| IN2014DN07637A (enExample) | 2015-05-15 |
| EP2825181A1 (en) | 2015-01-21 |
| EP3650031B1 (en) | 2026-07-01 |
| MY169093A (en) | 2019-02-18 |
| EP2825181B1 (en) | 2020-01-08 |
| EA201491690A1 (ru) | 2015-02-27 |
| JP6647570B2 (ja) | 2020-02-14 |
| NZ631429A (en) | 2016-09-30 |
| EA038965B1 (ru) | 2021-11-16 |
| SG11201405771QA (en) | 2014-10-30 |
| JP6293680B2 (ja) | 2018-03-14 |
| KR20200096991A (ko) | 2020-08-14 |
| KR102142504B1 (ko) | 2020-08-07 |
| BR112014022810B1 (pt) | 2021-04-13 |
| AU2013234099A1 (en) | 2014-10-02 |
| CN104363916B (zh) | 2018-09-25 |
| KR20150002675A (ko) | 2015-01-07 |
| WO2013136094A1 (en) | 2013-09-19 |
| CN104363916A (zh) | 2015-02-18 |
| ZA201406989B (en) | 2015-12-23 |
| EP3650031A1 (en) | 2020-05-13 |
| EP3650031C0 (en) | 2026-07-01 |
| US20150064256A1 (en) | 2015-03-05 |
| US9844568B2 (en) | 2017-12-19 |
| JP2015516373A (ja) | 2015-06-11 |
| JP2018111699A (ja) | 2018-07-19 |
| GB201204696D0 (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9844568B2 (en) | Porous carbon particles for use in the treatment or prevention of liver disease | |
| Zhao et al. | Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy | |
| Zhang et al. | Prodrug integrated envelope on probiotics to enhance target therapy for ulcerative colitis | |
| Ma et al. | Engineered probiotics enable targeted gut delivery of dual gasotransmitters for inflammatory bowel disease therapy | |
| Zhang et al. | Colon tissue-accumulating mesoporous carbon nanoparticles loaded with Musca domestica cecropin for ulcerative colitis therapy | |
| Kaur et al. | RETRACTED: Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis | |
| JP6978122B2 (ja) | 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 | |
| Mahami et al. | pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis | |
| CN113041232A (zh) | 靶向肠道爆破的口服结肠靶向水凝胶及其制备方法与应用 | |
| Li et al. | In situ sprayed self‐gelling powder self‐assembled by a pure molecular drug from herbal extract for rapid hemostasis and neuroprotection in traumatic brain injury | |
| Wu et al. | Astragaloside IV-loaded biomimetic nanoparticles target IκBα to regulate neutrophil extracellular trap formation for sepsis therapy | |
| Qian et al. | pH/temperature responsive curcumin-loaded micelle nanoparticles promote functional repair after spinal cord injury in rats via modulation of inflammation | |
| US20190142866A1 (en) | Porous carbon particles for use in the treatment or prevention of liver disease | |
| Zhang et al. | A colon-targeted oral nanosystem disrupts the inflammatory loop in enteric glia to alleviate ulcerative colitis | |
| Wu et al. | Inulin hydrogel loaded with self-assembled nanoparticles of curcumin and glycyrrhizic acid for inflammatory bowel disease treatment via anti-inflammation, antioxidation, and microbiota modulation | |
| Mao et al. | Orally ROS/pH Dual‐Responsive and Targeted Fucoxanthin Microspheres for the Alleviation of Colon Inflammation | |
| Zhao et al. | An in situ self-solidifying poly (lipoic-acid) liquid adhesive forms pathogen-resistant barrier for ulcerative colitis therapy | |
| Chen et al. | The postbiotic of hawthorn-probiotic ameliorates constipation by multi-pathway inhibition of PANoptosis in intestinal epithelial cells | |
| Zheng et al. | Calcined lotus leaf-derived carbon dots: enhanced hemostasis, anti-inflammatory, immunomodulatory properties for ulcerative colitis management | |
| EP4731232A1 (en) | Porous carbon particles for use in therapy | |
| KR20190039674A (ko) | 막관통 pH-구배 폴리머솜 및 암모니아와 그의 메틸화된 유사체의 소거에서의 이들의 용도 | |
| Niu et al. | Antibacterial efficacy and pharmacokinetics of a poly (mPEG-b-PCEA)–trimethoprim conjugate | |
| Zhuo et al. | Targeted modulation of intestinal epithelial regeneration and immune response in ulcerative colitis by bilirubin encapsulated in hyaluronic acid-functionalized PLGA nanoparticles | |
| Sun | Stimuli-Responsive Supramolecular Biomaterials for Targeted Treatment of Ulcerative Colitis | |
| Chen et al. | Porous organic polymers based on deep-cavity calixarenes for broad-spectrum and high-affinity drug adsorption in the gastrointestinal tract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |